Company Overview - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a biotechnology company focused on developing medicines using a novel anti-inflammatory approach through its proprietary Reactive Aldehyde Species (RASP) platform [1] Lead Asset - The company's lead asset is Reproxalap, which targets Dry Eye Disease (DED) and Allergic Conjunctivitis (AC) [1]

Aldeyra Therapeutics (ALDX) 2025 Conference June 05, 2025 04:20 PM ET Speaker0 Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference. My name is Clara Dunn, one of the biotech analysts here at Jefferies. So it's my pleasure here to help Aldara's CEO, Doctor. Todd Brady, here with us today for this fireside chat. Welcome. Speaker1 Thank you, Clara. Speaker0 So before we dig into details of your pipeline, maybe it will be helpful for you to give us a quick overview of the company and wha ...

Aldeyra Therapeutics (ALDX) FY 2025 Conference February 11, 2025 09:20 AM ET Company Participants Todd Brady - CEO, President & Director Conference Call Participants François Brisebois - Managing Director, Senior Biotechnology Research Analyst François Brisebois Alright. Great. Thank you for joining. My name is Frank Breasbois. I'm one of the biotech analysts at Oppenheimer. Our next presenting company here is Aldara Therapeutics. From the company, we have CEO, Todd Brady, to join. I think what we're going ...